Pharmaceutical care for type 2 diabetic patients: A randomised controlled trial

2007 ◽  
Vol 1 (4) ◽  
pp. 230
Author(s):  
E. Mehuys
Keyword(s):  
Randomised Controlled Trial ◽  
Pharmaceutical Care ◽  
Controlled Trial ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Randomised Controlled ◽  
Type 2 Diabetic

scholarly journals International Randomised Controlled Trial evaluating metabolic syndrome in type 2 Diabetic Cigarette Smokers following switching to Combustion-Free Nicotine Delivery Systems: the DIASMOKE protocol

2020 ◽  
Author(s):  
Arkadiusz Krysinski ◽  
Cristina Russo ◽  
Sarah John ◽  
Jonathan Belsey ◽  
Davide Campagna ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Health Impact ◽  
Diabetic Patients ◽  
Cigarette Smokers ◽  
Nicotine Delivery ◽  
Randomised Controlled ◽  
Type 2 Diabetic

Reducing exposure to cigarette smoke is an imperative for public health, and even more so for diabetic patients. Increasingly, combustion-free technologies for nicotine delivery such as e-cigarettes and heated tobacco products are substituting conventional cigarettes and accelerating the current downward trends in smoking prevalence. However, there is limited information about the long-term health impact in diabetics who use these technologies. This international randomised controlled trial of type 2 diabetic cigarette smokers will test the hypothesis that following a switch from conventional cigarettes to Combustion-Free Nicotine Delivery Systems (C-F NDS), a measurable improvement in metabolic syndrome (MetS) risk factors and functional parameters will be shown over the course of 2 years. A total of 576 patients will be randomized (1:2 ratio) to either a control arm (Study Arm A), in which they will be offered referral to smoking cessation programs or to an intervention arm (Study Arm B), in which they will be assigned to C-F NDS use. The primary outcome will be the prevalence of the a difference in MetS score between baseline and 2 years follow-up, with comparison being made between diabetic patients randomized to each arm of the study. Patient recruitment will start in October 2020 and enrolment is expected to be completed by August 2021. This will be the first study determining the overall health impact of using such technologies in diabetic patients. Data from this study will provide valuable insights into the overall potential of C-F NDS to reduce the risk of cardiovascular disease in individuals, particularly diabetic patients. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04231838

Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial.

2021 ◽  
pp. 101280
Author(s):  
Vicente Hidalgo Rodrigues Fernandes ◽  
Fernando R.P. Chaves ◽  
Alexandre A.S. Soares ◽  
Ikaro Breder ◽  
Sheila T. Kimura-Medorima ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Retinal Thickness ◽  
Controlled Trial ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Randomized Controlled ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document